A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
DRUG

VX-670

Solution for intravenous administration.

DRUG

Placebo

Solution for intravenous administration.

Trial Locations (26)

19104

RECRUITING

University of Pennsylvania, Philadelphia

23298

RECRUITING

Virginia Commonwealth University (Sanger Hall), Richmond

27104

RECRUITING

Wake Forest Baptist Health, Winston-Salem

32608

RECRUITING

University of Florida Clinical Research Center, Gainesville

63110

RECRUITING

Washington University School of Medicine / St. Louis Children's Hospital, St Louis

66205

RECRUITING

University of Kansas Medical Center, Fairway

94070

RECRUITING

Stanford Neuromuscular Research, San Carlos

02115

RECRUITING

Boston Children's Hospital, Boston

Unknown

RECRUITING

Wesley Research Institute, Auchenflower

RECRUITING

Neuroscience Clinical Trials Unit, Alfred Brain, Melbourne

RECRUITING

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

RECRUITING

Hopital de Chicoutimi, Chicoutimi

RECRUITING

Altasciences Montreal, Montreal

RECRUITING

McGIll University, Montreal

RECRUITING

University of Ottawa, Ottawa

RECRUITING

CHU Research Centre of Quebec, Québec

RECRUITING

Neuromuscular Reference Center Institute of Myology, Paris

RECRUITING

Ludwig Maximilians Universitaet Muenchen, München

RECRUITING

Centro Clinico NeMO, Milan

RECRUITING

Maastricht University Medical Center, Maastricht

RECRUITING

Hospital Universitario y Politécnico La Fe, Valencia

RECRUITING

Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow

RECRUITING

Leonard Wolfson Experimental Neurology Centre CRF, London

RECRUITING

St. George's University Hospital, London

RECRUITING

Salford Royal Hospital, Salford

RECRUITING

Royal Hallamshire Hospital, Sheffield

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY